Becton Dickinson (BDX) announced a $110M investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S. This investment will bring BD Neopak Glass Prefillable Syringe production to Columbus, Nebraska, creating approximately 120 new jobs. BD is investing $100M to establish BD Neopak Glass Prefillable Syringe production at its Columbus site, with supply expected to begin in mid-2026. This investment will also support additional line upgrades and capacity improvements across the site, ensuring BD can meet growing global demand for advanced injectable solutions. In addition, BD is investing $10M to enhance cannula manufacturing capabilities at the site, and together these investments will add approximately 120 new jobs.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson price target raised to $215 from $210 at Stifel
- Becton Dickinson price target raised to $207 from $190 at BofA
- Becton Dickinson, University of Pennsylvania partner on human immune profiling
- Becton Dickinson price target raised to $210 from $202 at RBC Capital
- Becton Dickinson announces expansion of BD MAX System menu